Oncology

Olaparib, a PARP inhibitor approved for treating BRCA1/2-mutated ovarian cancer, has been found effective in treating men with metastatic, castrate-resistant prostate cancer.

The drug significantly delayed recurrence of the cancer in patients treated post surgery.

Payer—provider teams presented updates on their cost-saving pilot projects and looked to the future of these models in oncology care.

The company says the treatment will cost an average of $65,000.

The ASCO statement emphasizes patient-centered reform that weighs-in the value of the services rendered.

A study shows too much conflicting dietary advice causes some people to tune it all out. Nuances in the report from WHO are lost on most consumers.

The vaccine, approved in Europe last week, is now awaiting approval in the United States.

A study published in the journal Cancer presents the financial impact of cancer on a survivor and his family.

This week in managed care, documents show Horizon Blue Cross Blue Shield of NJ rolled out OMNIA prior to receiving regulatory approval, 2 Harvard professors argue the merit of the annual physical, and experts weigh in on the successes and flaws of Medicare Part D.

The drug is awaiting an FDA verdict next week.

As the date for the comment period on the proposed guidance by HHS on 340B drug pricing draws near, read about the program and its impact on healthcare overall.